PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Update

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) was the recipient of a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 11,335 shares, an increase of 140.8% from the February 26th total of 4,707 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 5,784 shares, the short-interest ratio is presently 2.0 days.

Institutional Investors Weigh In On PureTech Health

Hedge funds and other institutional investors have recently bought and sold shares of the business. Lansdowne Partners UK LLP acquired a new position in shares of PureTech Health during the 3rd quarter worth $260,973,000. Pentwater Capital Management LP lifted its stake in shares of PureTech Health by 50.0% in the third quarter. Pentwater Capital Management LP now owns 75,000 shares of the company’s stock valued at $1,388,000 after purchasing an additional 25,000 shares during the period. Finally, Diadema Partners LP purchased a new stake in PureTech Health during the second quarter worth about $126,000. Institutional investors and hedge funds own 0.04% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d)” rating on shares of PureTech Health in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, PureTech Health presently has an average rating of “Sell”.

PureTech Health Price Performance

PRTC opened at $15.59 on Friday. PureTech Health has a 12 month low of $13.30 and a 12 month high of $20.00. The business has a 50 day simple moving average of $17.52 and a 200-day simple moving average of $17.28.

PureTech Health Company Profile

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.